Which funds bought or sold GH in Q3 2026?
Guardant Health Inc. 6 funds bought, 9 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$249M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- T. Rowe Price+$263M
- D. E. Shaw+$216M
- QRT+$205M
- Citadel+$204M
- ARK+$18M
- Temasek+$6M
- Jane Street−$289M
- Invesco−$260M
- Baillie Gifford−$101M
- AllianceBernstein−$101M
- Susquehanna−$76M
- Jennison−$48M
- Brown Advisory−$14M
- Farallon−$8M
- Polen−$5M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (6)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| T. Rowe Price Asset manager | Added+8233.1% | +$263M | $267M |
| D. E. Shaw Quant & multi-strategy | Added+96.5% | +$216M | $440M |
| QRT Quant & multi-strategy | Added+736% | +$205M | $233M |
| Citadel Quant & multi-strategy | Added+78.8% | +$204M | $462M |
| ARK Growth / crossover | Added+19.9% | +$18M | $108M |
| Temasek Sovereign & pension | Added+3.3% | +$6M | $189M |
Sold (9)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Jane Street Quant & multi-strategy | Trimmed-91% | −$289M | $29M |
| Invesco Asset manager | Trimmed-32.9% | −$260M | $530M |
| Baillie Gifford Growth / crossover | Trimmed-24.8% | −$101M | $306M |
| AllianceBernstein Asset manager | Trimmed-40.4% | −$101M | $148M |
| Susquehanna Quant & multi-strategy | Trimmed-66.1% | −$76M | $39M |
| Jennison Growth / crossover | Trimmed-76.2% | −$48M | $15M |
| Brown Advisory Asset manager | Trimmed-18.1% | −$14M | $65M |
| Farallon Hedge fund | Trimmed-13.2% | −$8M | $50M |
| Polen Growth / crossover | Trimmed-84.7% | −$5M | $939K |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.